Viking's obesity drug data fuels bets it can rival Lilly's Zepbound
Patients who switched from weekly to monthly injections of VK2735 retained most of their weight loss, with side effects similar to placebo
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Viking shares surge on updated obesity drug data biopharmadive.com
- Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. investors.com